New hope for ulcerative colitis: experimental drug enters Mid-Stage trial
NCT ID NCT07232576
First seen Nov 18, 2025 · Last updated May 06, 2026 · Updated 20 times
Summary
This study tests an experimental drug called SHR-1139 in 20 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. The trial has two parts: a 12-week induction phase to quickly reduce symptoms, followed by a 48-week maintenance phase to keep the disease under control. The goal is to see if the drug can improve symptoms and heal the gut lining, while monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital,Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
Explore the condition pages connected to this study.